24 / 30
PHASE III TRIALS COMPARISON: EFFICACY
Cabozantinib
Regorafenib Ramucirumab*
ORR, %**
4
6.6
4.6
DCR, %
64
65.7
59.9
PFS/TTP, months
5.2 / 5.4
3.1 / 3.2
2.8 / 3.0
OS, months
10.2
10.6
8.5
** RECIST 1.1 Criteria
* REACH2 Trial only